Lung

, Volume 189, Issue 1, pp 57–63 | Cite as

Clinical Usefulness of D2-40 in Non-Small Cell Lung Cancer

  • Kyung Hoon Min
  • Seoung Ju Park
  • Kyung Sun Lee
  • Sung Ho Hwang
  • So Ri Kim
  • Hee Moon
  • Hyo Jin Han
  • Myoung Ja Chung
  • Yong Chul Lee
Article

Abstract

D2-40 is a recently developed monoclonal antibody that reacts with a 40 kDa O-linked sialoglycoprotein and has been used for the assessment of lymphatic invasion in tumor specimens. We have evaluated the diagnostic usefulness of D2-40 and association of its immunopositivity with clinicopathological parameters in adenocarcinoma and squamous cell carcinoma of the lung. We investigated 97 cases of surgically resected adenocarcinoma or squamous cell carcinoma of the lung for the determination of D2-40 positivity in tumor cells and peritumoral lymphatic vessel density (LVD) using an immunostaining method. D2-40 immunoreactivity in tumor cells was invariably negative in adenocarcinoma but 47% of squamous cell carcinomas were positive. D2-40 positivity in the tumor was significantly associated with high LVD in squamous cell carcinoma (P < 0.006). There was no significant association between peritumoral LVD and clinicopathologic parameters, including lymphatic vessel invasion, lymph node metastasis, and survival in adenocarcinoma and squamous cell carcinoma. These results suggest that D2-40 immunoreactivity in tumor cells can be used for distinguishing between adenocarcinoma and squamous cell carcinoma and that the reactivity of tumor cells with D2-40 is positively correlated with LVD in squamous cell carcinoma but not with lymph node metastasis in adenocarcinoma and squamous cell carcinoma.

Keywords

D2-40 Lymphangiogenesis Lymphatic metastasis Lymphatic vessels Non-small cell lung cancer 

Notes

Acknowledgments

We thank professor Mie-Jae Im for careful reading of the manuscript. This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (A084144).

Disclosures

None.

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMedGoogle Scholar
  2. 2.
    Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Yokose T, Nishiwaki Y (1999) Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer 86:1976–1984CrossRefPubMedGoogle Scholar
  3. 3.
    Bunn PA Jr (2004) Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer 6:85–98CrossRefPubMedGoogle Scholar
  4. 4.
    Okada M, Nishio W, Sakamoto T, Harada H, Uchino K, Tsubota N (2003) Long-term survival and prognostic factors of five-year survivors with complete resection of non-small cell lung carcinoma. J Thorac Cardiovasc Surg 126:558–562CrossRefPubMedGoogle Scholar
  5. 5.
    Lee SM (2006) Is EGFR expression important in non-small cell lung cancer? Thorax 61:98–99CrossRefPubMedGoogle Scholar
  6. 6.
    Sihoe AD, Yim AP (2004) Lung cancer staging. J Surg Res 117:92–106CrossRefPubMedGoogle Scholar
  7. 7.
    Naruke T, Goya T, Tsuchiya R, Suemasu K (1988) Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 96:440–447PubMedGoogle Scholar
  8. 8.
    Rigau V, Molina TJ, Chaffaud C, Huchon G, Audouin J, Chevret S, Bréchot JM (2002) Blood vessel invasion in resected non small cell lung carcinomas is predictive of metastatic occurrence. Lung Cancer 38:169–176CrossRefPubMedGoogle Scholar
  9. 9.
    Takanami I (2006) Lymphatic microvessel density using D2-40 is associated with nodal metastasis in non-small cell lung cancer. Oncol Rep 15:437–442PubMedGoogle Scholar
  10. 10.
    Travis WD, Travis LB, Devesa SS (1995) Lung Cancer. Cancer 75:191–202CrossRefPubMedGoogle Scholar
  11. 11.
    Khayyata S, Yun S, Pasha T, Jian B, McGrath C, Yu G, Gupta P, Baloch Z (2009) Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 37:178–183CrossRefPubMedGoogle Scholar
  12. 12.
    Monica V, Ceppi P, Righi L, Tavaglione V, Volante M, Pelosi G, Scagliotti GV, Papotti M (2009) Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol 22:709–717CrossRefPubMedGoogle Scholar
  13. 13.
    Marks A, Sutherland DR, Bailey D, Iglesias J, Law J, Lei M, Yeger H, Banerjee D, Baumal R (1999) Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 80:569–578CrossRefPubMedGoogle Scholar
  14. 14.
    Bailey D, Marks A, Stratis M, Baumal R (1991) Immunohistochemical staining of germ cell tumors and intratubular malignant germ cells of the testis using antibody to placental alkaline phosphatase and a monoclonal anti-seminoma antibody. Mod Pathol 4:167–171PubMedGoogle Scholar
  15. 15.
    Kahn HJ, Bailey D, Marks A (2002) Monoclonal antibody D2–40, a new marker of lymphatic endothelium, reacts with Kaposi’s sarcoma and a subset of angiosarcomas. Mod Pathol 15:434–440CrossRefPubMedGoogle Scholar
  16. 16.
    Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154:385–394CrossRefPubMedGoogle Scholar
  17. 17.
    Browning L, Bailey D, Parker A (2008) D2-40 is a sensitive and specific marker in differentiating primary adrenal cortical tumours from both metastatic clear cell renal cell carcinoma and phaeochromocytoma. J Clin Pathol 61:293–296CrossRefPubMedGoogle Scholar
  18. 18.
    Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ (2005) Utility of D2–40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 18:105–110CrossRefPubMedGoogle Scholar
  19. 19.
    Ordóñez NG (2005) D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 36:372–380CrossRefPubMedGoogle Scholar
  20. 20.
    Kahn HJ, Marks A (2002) A new monoclonal antibody, D2–40, for detection of lymphatic invasion in primary tumors. Lab Invest 82:1255–1257PubMedGoogle Scholar
  21. 21.
    Dumoff KL, Chu C, Xu X, Pasha T, Zhang PJ, Acs G (2005) Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Mod Pathol 18:97–104CrossRefPubMedGoogle Scholar
  22. 22.
    Schmid K, Birner P, Gravenhorst V, End A, Geleff S (2005) Prognostic value of lymphatic and blood vessel invasion in neuroendocrine tumors of the lung. Am J Surg Pathol 29:324–328CrossRefPubMedGoogle Scholar
  23. 23.
    Sinzelle E, Duong Van Huyen JP, Breiteneder-Geleff S, Braunberger E, Deloche A, Kerjaschki D, Bruneval P (2000) Intrapericardial lymphangioma with podoplanin immunohistochemical characterization of lymphatic endothelial cells. Histopathology 37:93–94CrossRefPubMedGoogle Scholar
  24. 24.
    Nisato RE, Tille JC, Pepper MS (2003) Lymphangiogenesis and tumor metastasis. Thromb Haemost 90:591–597PubMedGoogle Scholar
  25. 25.
    Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I, Ostoros G, Agocs L, Soltesz I, Dome B (2005) Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 11:7344–7353CrossRefPubMedGoogle Scholar
  26. 26.
    Adachi Y, Nakamura H, Kitamura Y, Taniguchi Y, Araki K, Shomori K, Horie Y, Kurozawa Y, Ito H, Hayashi K (2007) Lymphatic vessel density in pulmonary adenocarcinoma immunohistochemically evaluated with anti-podoplanin or anti-D2-40 antibody is correlated with lymphatic invasion or lymph node metastases. Pathol Int 57:171–177CrossRefPubMedGoogle Scholar
  27. 27.
    Iwakiri S, Nagai S, Katakura H, Takenaka K, Date H, Wada H, Tanaka F (2009) D2–40-positive lymphatic vessel density is a poor prognostic factor in squamous cell carcinoma of the lung. Ann Surg Oncol 16:1678–1685CrossRefPubMedGoogle Scholar
  28. 28.
    Faoro L, Hutto JY, Salgia R, El-Zayaty SA, Ferguson MK, Cheney RT, Reid ME, Armato SG III, Krausz T, Husain AN (2008) Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. Arch Pathol Lab Med 132:1882–1888PubMedGoogle Scholar
  29. 29.
    Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E (1999) World health organization pathology panel: world health organization. Histological typing of lung and pleural tumors. International histological classification of tumors, 3rd edn. Springer, Berlin, pp 9–124Google Scholar
  30. 30.
    Greene F, Page D, Fleming I et al (2002) AJCC cancer staging manual, 6th edn. Springer, New York, pp 167–182Google Scholar
  31. 31.
    Sarkis SA, Abdullah BH, Abdul Majeed BA, Talabani NG (2010) Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol 2:13CrossRefPubMedGoogle Scholar
  32. 32.
    Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Gatter KC, Harris AL, Jackson DG (2005) LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. J Clin Pathol 58:202–206CrossRefPubMedGoogle Scholar
  33. 33.
    Ordóñez NG (2006) The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol 19:417–428CrossRefPubMedGoogle Scholar
  34. 34.
    Kimura N, Kimura I (2005) Podoplanin as a marker for mesothelioma. Pathol Int 55:83–86CrossRefPubMedGoogle Scholar
  35. 35.
    Hong YK, Harvey N, Noh YH, Schacht V, Hirakawa S, Detmar M, Oliver G (2002) Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn 225:351–357CrossRefPubMedGoogle Scholar
  36. 36.
    Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, Williams M, Dvorak AM, Dvorak HF, Oliver G, Detmar M (2003) T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 22:3546–3556CrossRefPubMedGoogle Scholar
  37. 37.
    Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M (2005) Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166:913–921CrossRefPubMedGoogle Scholar
  38. 38.
    Gandarillas A, Scholl FG, Benito N, Gamallo C, Quintanilla M (1997) Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Mol Carcinog 20:10–18CrossRefPubMedGoogle Scholar
  39. 39.
    Clarijs R, Ruiter DJ, de Waal RM (2001) Lymphangiogenesis in malignant tumours: does it occur? J Pathol 193:143–146CrossRefPubMedGoogle Scholar
  40. 40.
    Pepper MS (2001) Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 7:462–468PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Kyung Hoon Min
    • 1
    • 3
  • Seoung Ju Park
    • 1
    • 3
  • Kyung Sun Lee
    • 1
    • 3
  • Sung Ho Hwang
    • 2
  • So Ri Kim
    • 1
    • 3
  • Hee Moon
    • 1
    • 3
  • Hyo Jin Han
    • 1
    • 3
  • Myoung Ja Chung
    • 2
    • 3
  • Yong Chul Lee
    • 1
    • 3
  1. 1.Department of Internal MedicineChonbuk National University Medical SchoolJeonjuSouth Korea
  2. 2.Department of PathologyChonbuk National University Medical SchoolJeonjuSouth Korea
  3. 3.Research Center for Pulmonary DisordersChonbuk National University HospitalJeonjuSouth Korea

Personalised recommendations